Sociedad Americana de Hirudoterapia

Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study

Comparative study published in The British journal of dermatology (2014)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Observational studyEnsayos clínicosDarn S et al. · The British journal of dermatology, 2014

Abstract

BACKGROUND: There is only retrospective evidence for the efficacy of narrowband ultraviolet B (NB-UVB) in children with eczema. OBJECTIVES: To measure the difference in means for objective scores [Six Area Six Sign Atopic Dermatitis score (SASSAD), percentage surface area] and quality-of-life scores, between patients treated with NB-UVB and unexposed cohorts at the end of treatment, and 3 and 6 months post-treatment. METHODS: Twenty-nine children aged 3-16 years for whom NB-UVB was indicated, were scored prospectively using SASSAD and percentage surface area involvement at baseline, at 12 weeks (end of treatment) and 3 and 6 months post-NB-UVB. Their scores were compared with those of unexposed children (n = 26) for whom NB-UVB phototherapy was indicated and offered, but who chose not to undertake treatment. RESULTS: There was a 61% reduction in mean SASSAD score in the NB-UVB cohort compared with an increase of 6% in the unexposed cohort. Mean SASSAD score for the NB-UVB cohort at the end of treatment was 11.6 vs. 24.8 for the unexposed; difference in means -13.2 [95% confidence interval (CI) -18.7 to -7.7, P < 0.0001]. Mean surface area involvement at the end of treatment was 11% for the NB-UVB cohort vs. 36% for the unexposed cohort; difference in means -25% (95% CI -34% to -16%, P < 0.0001). Subjective and quality-of-life scores showed significant difference between cohorts at the end of treatment (P < 0.05). Objective scores remained significantly lower than in the unexposed cohort 3 and 6 months after treatment. CONCLUSION: NB-UVB is clinically effective and improves quality of life in children with moderate-to-severe eczema. The effect is maintained for 6 months after treatment.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyEvaluation StudyJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAdolescentChildChild, PreschoolEczemaFemaleHumansMaleProspective StudiesRemission InductionTreatment OutcomeUltraviolet Therapy

Resumen

There is only retrospective evidence for the efficacy of narrowband ultraviolet B (NB-UVB) in children with eczema.

Por qué esto importa para la hirudoterapia

Este estudio evaluó la eficacia clínica de la fototerapia con ultravioleta B de banda estrecha (NB-UVB) en niños de 3 a 16 años con eccema moderado-grave, midiendo puntuaciones objetivas de gravedad (SASSAD, superficie corporal afectada) y resultados de calidad de vida al final del tratamiento y a los 3 y 6 meses tras el tratamiento. La cohorte NB-UVB mostró mejoras significativas en comparación con una cohorte no expuesta, manteniéndose los efectos a los 6 meses. Este artículo no tiene conexión alguna con sanguijuelas, hirudoterapia, hirudina o el secretoma de la sanguijuela; no existe una relevancia defendible para el ámbito de ASH. El estudio versa sobre fototerapia dermatológica para el eccema infantil, y en el resumen no aparece contenido alguno sobre anticoagulantes, inhibidores de la trombina o temas relacionados con la sanguijuela.

Citación

Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study

Darn S et al. · The British journal of dermatology, 2014

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.